Cardiac allograft vasculopathy: A review

Area of Science:

• Cardiology
• Transplantation Immunology

Background:

• Cardiac allograft vasculopathy (CAV) is a major cause of death after orthotopic heart transplantation (OHT).
• CAV development involves inflammation, endothelial dysfunction, and genetic/patient factors.
• Early detection of CAV is difficult due to variable or absent symptoms.

Purpose of the Study:

• To review the diagnosis, management, and treatment options for cardiac allograft vasculopathy.

Main Methods:

• Review of current diagnostic tools including coronary angiography, intravascular imaging (IVUS, OCT), and non-invasive imaging (PET, CT, MRI).
• Discussion of medical management strategies, including statins, vasodilators, and immunosuppression.
• Evaluation of interventional and surgical options, including percutaneous coronary intervention and re-transplantation.

Main Results:

• Coronary angiography is the primary diagnostic tool, supplemented by intravascular imaging and physiologic assessments.
• Medical therapy aims to reduce rejection and CAV progression with minimal side effects.
• Repeat transplantation is the only definitive treatment but is reserved for select patients.

Conclusions:

• Effective management of CAV requires a multi-faceted approach combining diagnostics and tailored therapies.
• Optimizing immunosuppression and medical management is crucial for long-term outcomes.
• Invasive procedures and repeat transplantation offer options for refractory cases but carry significant risks.